Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

• 90% of the cases of untreated TTTS lead to loss of one or both twins.
• Despite treatment, only a 70% survival rate for both twins is assured.
• Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
• Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

Unlike many other cancers, cervical cancer is considered highly preventable through a combination of HPV vaccination, regular screening, and timely treatment of precancerous lesions.

India has recorded a significant decline in cervical cancer burden, with new cases falling by 37% over the past decade, according to data from the Indian Council of Medical Research's (ICMR) National Cancer Registry Programme (NCRP).

Experts say widespread screening, awareness, and increasing uptake of the human papillomavirus (HPV) vaccine have contributed to the milestone.

Cervical Cancer Cases Drop In India

The latest estimates show that the number of new cervical cancer cases has dropped from approximately 1.27 lakh annually to around 79,000, marking a major public health milestone in the fight against one of the most common cancers affecting Indian women.

"Cervical cancer is one of the few cancers that can largely be prevented through timely screening and vaccination," Dr. Amitabh Shankar, Head of Preventive Oncology at Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, AIIMS, was quoted as saying.

He attributed the decline to improved awareness, wider availability of screening services, and the gradual expansion of HPV vaccination.

Also read: Minimally Invasive Focal Therapy For Prostate Cancer Promises Fewer Side Effects Than Surgery Or Radiotherapy

Positive Impact Of Screening And HPV Vaccination

According to experts, early detection through routine cervical cancer screening allows precancerous changes to be identified and treated before they develop into cancer.

At the same time, HPV vaccination protects against high-risk strains of the human papillomavirus, the leading cause of cervical cancer.

The report suggests that increased access to healthcare services, government-led awareness initiatives, and preventive programs have played an important role in reducing the cases of cervical cancer.

Despite the progress, specialists caution that cervical cancer continues to be a major health concern in India, particularly in rural and underserved regions where screening coverage and HPV vaccination remain limited.

They emphasize that expanding HPV vaccination among eligible adolescents, strengthening population-based screening programs, and improving early diagnosis will be essential to prevent it.

Also read: KRAS-Targeted Vaccine Shows Promise In Fighting Pancreatic Cancer, Triggers Strong Immune Response In Early Trial

About HPV Vaccine

The human papillomavirus causes more than 200 known infections. While some types lead to benign skin warts, others are responsible for severe health threats, such as cervical, throat, anal, and penile cancers.

The HPV vaccine provides strong protection against the most lethal strains, avoiding long-term health complications. It helps the immune system recognize and fight off high-risk strains of the virus before they cause harm. It protects against:

• Genital warts
• Cervical cancer
• Vaginal, vulvar, anal, and penile cancers
• Mouth, throat, head, and neck cancers linked to HPV

What Is Cervical Cancer?

Cervix is located in the pelvic cavity, about 3 to 6 inches inside the vaginal canal. It serves as the entrance to the uterus to the vagina. As per the World Health Organization (WHO), almost all cervial cancer are linked to human papillomaviruses (HPV) which are transmitted through sexual contact

Symptoms Of Cervical Cancer

Cervical cancer has no symptoms in the early days and therefore, is hard to detect until it has spread. Early-stage cervical cancer symptoms include:

• Vaginal bleeding after sex
• Vaginal bleeding post-menopause
• Vaginal bleeding between periods or unusually heavy/long periods
• Watery vaginal discharge with a strong odour or containing blood
• Pelvic pain or pain during intercourse

• Persistent early-stage symptoms
• Painful or difficult bowel movements or rectal bleeding
• Painful or difficult urination or blood in the urine
• Persistent dull backache
• Swelling of the legs
• Pain in the pelvis or lower abdomen

Takeda Biopharmaceuticals India today announced that QDENGA (TAK-003) has become the first dengue vaccine to receive approval in India, marking a major milestone in the country's fight against the mosquito-borne disease.

The Drug Controller General of India (DCGI) has granted market authorization for QDENGA to prevent dengue in individuals aged 4-60 years. According to Takeda, it is India's first approved dengue vaccine and can be administered regardless of previous dengue infection, without requiring pre-vaccination testing.

"Since its launch in 2022, QDENGA has been approved in 43 countries, with more than 32 million doses distributed globally. This approval marks an important step forward in strengthening dengue prevention in India," said Dr. Mahender Nayak, Head of Intercontinental Markets.

QDENGA Vaccine: Why The Approval Matters

The approval comes at a critical time as dengue cases in India have risen sharply over the past two decades.

India accounts for nearly one-third of the global dengue burden. In 2025, more than 113,000 dengue cases were officially reported, although modelling studies suggest the true number of infections may run into tens of millions annually due to underreporting.

Rapid urbanization, climate change and widespread mosquito breeding have made dengue a year-round public health concern. Since there is no specific antiviral treatment for dengue, prevention remains the most effective strategy.

"India carries a substantial dengue burden, and all four dengue virus serotypes co-circulate in several regions. QDENGA is designed to protect against all four serotypes regardless of prior exposure," said Dr. Goh Choo Beng, Medical Affairs Head, Southeast Asia & India Cluster.

Also read: Dengue Serotypes Shifting In Young Adults: How India's Indigenous Vaccine Could Help Prevent Severe Disease

QDENGA: Scientific Evidence

The DCGI approval is supported by Takeda's global clinical development programme comprising 19 Phase 1, 2 and 3 clinical trials involving more than 28,000 participants in dengue-endemic and non-endemic regions.

The pivotal Phase III TIDES (DEN-301) study enrolled more than 20,000 participants across eight countries and evaluated the vaccine's long-term safety and effectiveness.

Key findings include:

• 80.2% vaccine efficacy against virologically confirmed dengue one year after the second dose.
• 90.4% efficacy against dengue-related hospitalization at 18 months.
• 84.1% protection against dengue-related hospitalization after 4.5 years.
• Safety and efficacy data demonstrating protection for up to seven years across all four dengue virus serotypes.

The approval is also supported by an Indian Phase III (DEN-302) trial involving participants aged 4-60 years, which found QDENGA to be safe, well-tolerated and immunogenic in children, adolescents and adults.

Read More: Dengue Is Spreading Beyond Monsoons And Into New Regions Across India, Says Expert

What Is QDENGA?

QDENGA (TAK-003) is a live-attenuated tetravalent dengue vaccine designed to protect against all four dengue virus serotypes.

It is administered as two 0.5 mL subcutaneous doses, given three months apart.

The vaccine is built on a DENV-2 backbone, incorporating structural proteins from DENV-1, DENV-3 and DENV-4 to provide broad immune protection.

The World Health Organization (WHO) recommends QDENGA for use in dengue-endemic settings without the need for pre-vaccination screening. The vaccine is also included in the WHO List of Prequalified Vaccines, allowing procurement through agencies such as UNICEF and PAHO.

The vaccine has been approved in 43 countries across Asia, Latin America and Europe. It is already part of Brazil's National Immunization Program and is available through public immunization programmes in Argentina, Colombia and Indonesia.

Who can take QDENGA?

The vaccine is approved in India for people aged 4-60 years to help prevent dengue disease.

Manufacturing In India

Takeda had partnered with Indian vaccine manufacturer Biological E in 2024 to expand production of QDENGA.

Under the agreement, Biological E plans to manufacture 50 million doses annually, supporting Takeda's goal of producing 100 million doses globally each year by the end of the decade.

A minimally invasive treatment that targets only cancerous tissue in the prostate may offer the same chance of treating localized prostate cancer as surgery or radiotherapy while causing significantly fewer side effects, according to a major UK study.

The findings suggest that focal therapy, which destroys only the tumor while preserving the healthy parts of the prostate, could become a viable treatment option for carefully selected patients.

It could help reduce common risks like urinary incontinence and erectile dysfunction that follow conventional treatment.

Prostate Cancer Treatment With Fewer Side Effects

The study, presented by University College London (UCL) and collaborating institutions, compared long-term outcomes of men treated with focal therapy against those receiving radical prostatectomy or radiotherapy.

Researchers found that cancer control was comparable across the treatment groups, while men undergoing focal therapy experienced substantially better functional outcomes.

"This study shows that men with localized prostate cancer do not necessarily have to choose between effective cancer treatment and preserving their quality of life," said Professor Caroline Moore, Professor of Urology at University College London.

"Our results demonstrate that focal therapy can control cancer effectively in appropriately selected men while significantly reducing the side effects associated with whole-gland treatments."

Also read: KRAS-Targeted Vaccine Shows Promise In Fighting Pancreatic Cancer, Triggers Strong Immune Response In Early Trial

Unlike surgery, which removes the entire prostate, or radiotherapy, which treats the whole gland, focal therapy targets only the cancer with the help of high-intensity focused ultrasound (HIFU). By sparing healthy tissue and surrounding nerves, the treatment aims to preserve urinary and sexual function.

According to the researchers, the study provides strong evidence that focal therapy can offer outcomes similar to standard treatments in men whose cancer is confined to a specific area of the prostate.

Not Appropriate For Every Patient

Professor Moore cautioned that focal therapy for prostate cancer may not be suitable for every patient. "It is important that men undergo careful assessment with high-quality imaging and biopsy so that we can identify those who are most likely to benefit from this treatment," she said.

The researchers also emphasized that patients receiving focal therapy require ongoing follow-up, including prostate-specific antigen (PSA) testing and imaging, to monitor any recurrence or progression of disease.

Also read: Broadcaster Lauren Laverne Shares 'Smoldering Myeloma' Diagnosis After Cancer Recovery

Jeremy Clarkson's Revelation

The findings have drawn renewed public attention after television presenter Jeremy Clarkson recently disclosed that he underwent treatment for prostate cancer.

Clarkson revealed that he chose a treatment that reduced long-term side effects, raising awareness about prostate cancer, and the importance of early diagnosis.

Prostate cancer is among the most commonly diagnosed cancers in men worldwide. While surgery and radiotherapy remain the standard treatments for localized disease, both can result in complications like urinary leakage, bowel problems and erectile dysfunction that can affect the quality of life.

Experts say the new findings support a growing shift toward more personalized treatment strategies that balance cancer treatment with quality of life.